Herbaceuticals: An overview for counselors

Journal of Counseling and Development

Volumn 83, Issue 4, 2005, Pages 434-443

  Ingersoll, R Elliott ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27844501021     PISSN: 07489633     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1556-6678.2005.tb00365.x     Document Type: Review

References (112)

1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., Text rev.) Washington DC: Author.
2. Angrist, B., Rotrosen, J., Kleinberg, D., Merriam, V., & Gershon, S. (1977). Dopaminergic agonist properties of ephedrine: Theoretical implications. Psychopharmacology, 55, 115-120.
3. Astin, J. A. (1998). Why patients use alternative medicine: Results of a national study. Journal of the American Medical Association, 279, 1548-1553.
4. Balderer, G., & Bobely, A. A. (1985). Effect of valerian on human sleep. Psychopharmacology (Berl), 87, 406-409.
5. Beaubrun, G., & Gray, G. E. (2000). A review of herbal medicines for psychiatric disorders. Psychiatric Services, 51, 1130-1134.
6. Bent, S., Tiedt, T. N., Odden, M. C., & Shlipak, M. G. (2003). The relative safety of ephedra compared with other herbal products. Annals of Internal Medicine, 138, 468-471.
7. Berardinelli, C., & Mostade, J. (2003, July). Supervision of psychopharmacology. Presentation given at John Carroll University, Cleveland, OH.
8. Bilia, A. R., Gallori, S., & Vincieri, F. F. (2002). St. John's Wort and depression: Efficacy, safety, and tolerability - an update. Life Sciences, 70, 3077-3096.
9. Boniel, T., & Dannon, P. (2001). The safety of herbal medicines in the psychiatric practice. Harefuah, 140, 780-783.
10. Brauer, R. B., Stangl, M., Siewert, J. R., Pfab, R., & Becker, K. (2003). Acute liver failure after administration of the herbal tranquilizer Kava-Kava (piper methysticum). Journal of Clinical Psychiatry, 64, 216-218.
11. Breggin, P. R. (1997). Brain disabling treatments in psychiatry. New York: Springer.
12. Brenner, R., Bjerkenstedt, L., & Edman, G. V. (2002), Hypericum perforatum extract (St. John's Wort) for depression. Psychiatric Annals, 32, 21-26.
13. Capwell, R. R. (1995). Ephedrine-induced mania from an herbal diet supplement. American Journal of Psychiatry, 152, 647.
14. Cervo, L., Rozio, M., Ekalle-Soppo, C. B., Guiso, G., Morazzoni, P., & Caccia, S. (2002). Role of hyperforin in the antidepressantlike activity of hypericum perforatum extracts. Psychopharmacology, 164, 423-428.
15. Cocks, M., & Moller, V. (2002). Use of indigenous and indigenised medicines to enhance personal well-being: A South African case study. Social Science and Medicine, 54, 387-397.
16. Colbert, T. C. (2002, June). Drugs or psychotherapy? What's the answer? Symposium conducted in Beachwood, OH.
17. Connor, K. M., & Davidson, J. R. (2002). A placebo-controlled study of Kava Kava in generalized anxiety disorder. International Clinical Psychopharmacology, 17, 185-188.
18. Consumer's Union. (1999). Herbal Rx: The promises and pitfalls. Consumer Reports, 64, 44-48.
19. Cott, J., & Wisner, K. L. (2002). Effect of hypericum perforatum (St John's Wort) in major depressive disorder: A randomized controlled trial: Comment Journal of the American Medical Association, 288, 448.
20. Dannawi, M. (2002). Possible serotonin syndrome after combination of buspirone and St John's Wort. Journal of Psychopharmacology, 16, 401.
21. Doraiswamy, P., & Murali, N. C. (2001). The Alzheimer's Disease Assessment Scale: Evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer's Disease and Associated Disorders, 15, 174-183.
22. Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S. Can Rompay, M., et al. (1998). Trends in alternative medicine use in the United States, 1990-1997. Journal of the American Medical Association, 280, 1569-1575.
23. Ercil, N. E., & France, C. P. (2003). Amphetamine-like discrimination stimulus effects of ephedrine and its stereoisomers in pigeons. Experimental & Clinical Psychopharmacology, 11, 3-8.
24. Ernst, E. (2002). The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava. Annals of Internal Medicine, 136, 42-53.
25. Food and Drug Administration. (2003). PDA announces plans to prohibit the sales of dietary supplements containing ephedra. Retrieved on December 30,2003, from http://www.cfsan.fda.gov/~dms/ds-ephed.html
26. Fox, M. (2003, March 11). Baseball player's death re-ignites ephedra debate. Reuters Daily News, 2, C1.
27. Friede, M., Henneicke von Zepelin, H. H., & Freudenstein, J. (2001). Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's Wort. Pharmacopsychiatry, 34(Suppl. 1), 38-41.
28. Gaster, B., & Holroyd, J. (2000). St. John's Wort for depression: A systematic review. Archives of Internal Medicine, 160, 152-156.
29. Geiger, J. D. (2002). Adverse events associated with supplements containing ephedra alkaloids. Clinical Journal of Sport Medicine, 12, 263.
30. Glennon, R. A., & Young, R. (2000). Amphetamine-stimulus generalization to an herbal ephedrine product. Pharmacology, Biochemistry, & Behavior, 65, 655-688.
31. Gold, J. L., Laxer, D. A., Dergal, J. M., Lanctot, K. L., & Rochon, P. A. (2001). Herbal-drug interactions: A focus on dementia. Current Opinion in Clinical Nutrition and Metabolic Care, 4, 29-34.
32. Gray, G. E. (1999). A psychiatric perspective on herbal remedies. Directions in Psychiatry, 19, 349-359.
33. Grube, B., Walper, A., & Wheatley, D. (1999). St. John's Wort extract: Efficacy for menopausal symptoms of psychological origin. Advances in Therapy, 16, 177-186.
34. Gruber, A. J., & Pope, H. G. (1998). Ephedrine abuse among 36 female weightlifters. American Journal on Addictions, 7, 256-261.
35. Gutherie, S. K. (1999, September). Herbaceuticals in psychiatry. Lecture given at The Medical College of Ohio, Toledo.
36. Hailemaskel, B., Dutta, A., & Wutoh, A. (2001). Adverse reactions and interactions among herbal users. Issues in Interdisciplinary Care, 3, 297-300.
37. Healy, D. (1997). The antidepressant era. Cambridge, MA: Harvard University Press.
38. Healy, D. (2002). The creation of psychopharmacology. Cambridge, MA: Harvard University Press.
39. Holsboer-Trachsler, F., & Vanoni, C. (1999). Clinical efficacy and tolerance of the hypericum special extract LI 160 in depressive disorders: A drug monitoring study. Schweizerische Rundschau, Fur Medizin Praxis, 88, 1475-1480.
40. Houghton, P. J. (1999). The scientific basis for the reputed activity of valerian. Journal of Pharmacy and Pharmacology, 51, 505-512.
41. Hypericum Depression Trial Study Group. (2002). Effect of hypericum perforatum (St. John's Wort) in major depressive disorder: A randomized controlled trial. Journal of the American Medical Association, 287, 1807-1814.
42. Ingersoll, R. E. (2000). Teaching a course in psychopharmacology to counselors: Justification, structure, and methods. Counselor Education and Supervision, 40, 58-69.
43. Ingersoll, R. E. (2001). The nonmedical therapist's role in pharmacological interventions with adults, In E. R. Welfel & R. E. Ingersoll (Eds.), The mental health desk reference (pp. 88-93). New York: Wiley.
44. Ingersoll, R. E., Bauer, A. L., & Burns, L. (in press). Children and psychotropic medication: What role should advocacy counseling play? Journal of Counseling & Development.
45. Izzo, A. A., & Ernst, E. (2001). Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs, 61, 2163-2175.
46. Jacobs, K. M., & Hirsch, K. A. (2000). Psychiatric complications of ma-huang. Psychosomatics: Journal of Consultation Liaison Psychiatry, 41, 58-62.
47. Julien, R. M. (2001). A primer of drug action: A concise, nontechnical guide to the actions, uses, and side effects of psychoactive drugs. New York: Worth.
48. Kaberi-Otarod, J., Conetta, R., Kundo, K. K., & Farkash, A. (2002). Ischemic stroke in a user of thermadrene: A case study in alternative medicine. Clinical Pharmacology and Therapeutics, 72, 343-346.
49. Kasper, S., & Dienel, A. (2002). Cluster analysis of symptoms during antidepressant treatment with hypericum extract in mildly to moderately depressed out-patients: A meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology, 164, 301-308.
50. Keller, K. B., & Lemberg, L. (2001). Herbal or complementary medicine: Fact or fiction? American Journal of Critical Care, 10, 438-443.
51. Kim, H. L., Streltzer, J., & Goebert, D. (1999). St. John's Wort for depression. Journal of Nervous and Mental Diseases, 187, 532-539.
52. Kinzler, E., Kroner, J., & Helman, E. (1991). Effect of a special kava extract in patients with anxiety, tension, and excitation states of non-psychotic genesis: Double blind study with placebos over 4 weeks. Arzneimittelforschung, 41, 584-588.
53. Kistorp, T. K., & Laursen, S. B. (2002). Herbal medicines: Evidence and drug interactions in clinical practice. Ugeskrift For Laeger, 164, 4161-4165.
54. Klaus, L., Mechart, D., Mulrow, C. D., & Berner, M. (2002). Effect of hypericum perforatum (St. John's Wort) in major depressive disorder: A randomized controlled trial: Comment. Journal of the American Medical Association, 288, 447-448.
55. Kleijnen, J., & Knipschild, P. (1992). Ginkgo biloba. Lancet, 340, 1136-1139.
56. Klesper, T. B., Doucette, W. R., Horton, M. R., Buys, L. M., Ernst, M. E., & Ford, J. K., et al. (2000). Assessment of patients' perceptions and beliefs regarding herbal therapies. Pharmacotherapy, 20, 83-87.
57. Klesper, T. B., & Klesper, M. E. (1999). Unsafe and potentially safe herbal therapies. American Journal of Health Systems and Pharmaceuticals, 56, 125-138.
58. Knekt, P., Kumpulainen, J., Jarvinen, R., Rissanen, H., Heliovaara, M., Reunanen, A., et al. (2002). Flavinoid intake and risk of chronic disease. American Journal of Nutrition, 76, 560-568.
59. Kuhlmann, J., Berger, W., Podzuweit, H., & Schmidt, U. (1999). The influence of valerian treatment on reaction time, alertness, and concentration in volunteers. Pharmacopsychiatry, 32, 235-241.
60. Kupfer, D. J., & Frank, E. (2002). Effect of hypericum perforatum (St. John's Wort) in major depressive disorder: A randomized controlled trial: A reply. Journal of the American Medical Association, 288, 449.
61. Laakmann, G., Jahn, G., & Schuele, C. (2002). Hypericum perforatum extracts in the treatment of mild to moderate depression: Clinical and pharmacological aspects. Nerenarzt, 73, 600-612.
62. LaFrance, W. C., Lauterbach, E. C., Coffey, C. E., Salloway, S. P., Kaufer, D. I., & Reeve, A., et al. (2000). The use of herbal alternative medicines in neuropsychiatry. Journal of Neuropsychiatry and Clinical Neurosciences, 12, 177-192.
63. Leak, J. A. (1999). Herbal medicine: Is it an alternative or an unknown? A brief review of popular herbals used by patients in a pain and symptom management practice setting. Current Review of Pain, 3, 226-236.
64. Leathwood, P. D., & Chauffard, F. (1982) Quantifying the effects of mild sedatives. Journal of Psychiatric Research, 17, 115-122.
65. Leathwood, P. D., Chauffard, F., Heck, E., & Munoz-Box, R. (1982). Aqueous extract of valerian rood (caleriana officinalis 1.) improves sleep quality in man. Pharmacology and Biochemical Behavior, 17, 65-71.
66. LeBars, P. L., & Kastelan, J. (2000). Efficacy and safety of Ginkgo Biloba extract. Public Health Nutrition, 3, 495-499.
67. LeBars, P. L., Katz, M. M., Berman, N., Itil, T. M., Freedman, A. M., & Schatzberg, A. F. (1997). A placebo-controlled, double-blind randomized trial of an extract of ginkgo biloba for dementia. Journal of the American Medical Association, 278, 1327-1332.
68. Lecrubier, Y., Clerc, G, Didi, R., & Keiser, M. (2002). Efficacy of St John's Wort extract WS 5570 in major depression: A double-blind, placebo-controlled trial. American Journal of Psychiatry, 159, 1361-1366.
69. Linde, K., & Mulrow, C. D. (2000). St. John's Wort for depression. Cochrane Database System Review, 2, CD000448.
70. Linde, K., Ramirez, G., Mulrow, C. D., Pauls, A., Weidenhammer, W., & Melchart, D. (1996). St. John's Wort for depression. British Medical Journal, 313, 253-258.
71. Loera, J. A., Black, S. A., Markides, K. S., Espino, D. C., & Goodwin, J. S. (2001). The use of herbal medicine by older Mexican Americans. Journals of Gerontology: Series A: Biological Sciences and Medical Sciences, 56A, M714-M718.
72. Maradino, C. (1997). Ephedra falls under PDA jurisdiction. Vegetarian Times, 241, 1.
73. Meyer, H. J. (1967). Pharmacology of kava. Psychopharmacology Bulletin, 4, 10-11.
74. Mischoulon, D. (2002). The herbal anxiolytics kava and valerian for anxiety and insomnia. Psychiatric Annals, 32, 55-60.
75. Mowbray, R. M. (1972). The Hamilton rating scale for depression: A factor analysis. Psychological Medicine, 2, 272-280.
76. Northridge, M. E., & Mack, R. (2002). Integrating ethnomedicine into public health. American Journal of Public Health, 92, 1561.
77. Parker, V., Wong, A. H., Boon, H. S., & Seeman, M. V. (2001). Adverse reactions to St John's Wort. Canadian Journal of Psychiatry Revue Canadienne de Psychiatre, 46, 77-79.
78. Perry, E. K. (2002). Plants of the gods: Ethnic routes to altered consciousness. In E. K. Perry & H. Ashton (Eds.), Neurochemistry of consciousness: Neurotransmitters in mind (pp. 205225). Philadelphia: Benjamins.
79. Pies, R. (2000). Adverse neuropsychiatrie reactions to herbal and over-thecounter "antidepressants." Journal of Clinical Psychiatry, 61, 815-820.
80. Redvers, A., Laugharne, R., Kanagaratnam, G., & Srinivasan, G. (2001). How many patients self-medicate with St. John's Wort? Psychiatric Bulletin, 25, 254-256.
81. Rex, A., Morgenstern, E., & Fink, H. (2002). Anxiolytic-like effects of kava-kava in the elevated plus maze test: A comparison with diazepam. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26, 855-860.
82. Rivas-Vazquez, R. A. (2001). St. John's Wort (hypericumperforatum): Practical considerations based on the evidence. Professional Psychology: Research and Practice, 32, 329-332.
83. Salerian, A. J., Deibler, W. E., Vittone, B. J., Geyer, S. P., Drell, L., Mirmirani, N., et al. (2000). Sildenaril for psychotropic induced sexual dysfunction in 31 women and 61 men. Journal of Sex & Marital Therapy, 26, 133-140.
84. Schenkel, E., Corren, J., & Murray, J. J. (2002). Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy and Asthma Proceedings: The Official Journal of Regional and State Allergy Societies, 23, 325-330.
85. Schwartz, G. E. (1983). Development and validation of the Geriatric Evaluation by Relative's Rating Instrument (GERRI). Psychological Reports, 53, 479-488.
86. Shekelle, P. H., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttorp, M. J., et al. (2003). Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: A meta-analysis. Journal of the American Medical Association, 289, 1537-1545.
87. Shelton, R. C., Keller, M. B., Gelenbert, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., et al. (2001). Effectiveness of St. John's Wort in major depression: A randomized, controlled trial. Journal of the American Medical Association, 285, 1978-1986.
88. Siegel, R. K. (1989). Intoxication: Life in pursuit of artificial paradise. New York: Dutton.
89. Smith, H. (2000). Cleansing the doors of perception: The religious significance of entheogenic plants and chemicals. New York: Tarcher.
90. Soloman, P. R., Adams, F., Silver, A., Zimmer, J., & De Veaux, R. (2002). Ginkgo for memory enhancement: A randomized control trial. Journal of the American Medical Association, 288, 835-840.
91. Sommer, B. R., & Schatzberg, A. F. (2002). Ginkgo biloba and related compounds in Alzheimer's disease. Psychiatric Annals, 32, 13-18.
92. Spielmans, G. I. (2002). Effect of hypericum perforatum (St. John's Wort) in major depressive disorder: A randomized controlled trial: A reply. Journal of the American Medical Association, 288, 446-447.
93. Spinella, M. (2001). The psychopharmacology of herbal medicine: Plant drugs that alter mind, brain, and behavior. Cambridge, MA: MIT Press.
94. Studenski, F., Hayes, R. P., Liebowitz, R. Q., Bode, R., Lavery, L., Walston, J., et al. (2004). Clinical global impression of change in physical frailty: Development of a measure based on clinical judgment. Journal of the American Geriatrics Society, 52, 1560-1566.
95. Sullivan, R. J., & Hagen, E. H. (2002). Psychotropic substance-seeking: Evolutionary path or adaptation? Addiction, 97, 389-400.
96. Supplement Watch. (2005). What is ephedra? Retrieved July 19, 2005, from http://www.whatisephedra.com/index.html
97. Van der Hooft, C. S., & Stricher, B. H. (2002). Ephedrine and ephedra in weight loss products and other preparations. Nederlands Tijdschrift Coor Geneeskunde, 146, 1335-1336.
98. Vasankathumar, N. B. (2001). Medical malpractice: A comprehensive analysis. New York: Auburn House.
99. Vernon, L. T., Fuller, M. A., Hattab, H., & Varnes, K. M. (2000). Olanzapine-induced urinary incontinence: Treatment with ephedrine. The Journal of Clinical Psychiatry, 61, 601-602.
100. Volp, A. (2002). Effect of hypericum perforatum (St. John's Wort) in major depressive disorder: A randomized controlled trial: Comment. Journal of the American Medical Association, 288, 447.
101. Volz, H. P. (1997). Controlled clinical trials of hypericum extracts in depressed patients: An overview. Pharmacopsychiatry, 30(Suppl. 2), 72-76.
102. Volz, H. P., & Laux, P. (2000). Potential treatment for subthreshold and mild depression: A comparison of St. John's Wort extracts and fluoxetine. Comprehensive Psychiatry, 41, 133-137.
103. Volz, H. P., Murck, H., Kasper, S., & Moeller, H. J. (2002). St. John's Wort extract (LI 160) in somatoform disorders: Results of a placebo-controlled trial. Psychopharmacology, 164, 294-300.
104. Walter, G., & Rey, J. M. (1999). Use of St. John's Wort by adolescents with a psychiatric disorder. Journal of Child and Adolescent Psychopharmacology, 9, 307-311.
105. Warnecke, G. (1991). Psychosomatic dysfunctions in the female climacteric: Clinical effectiveness and tolerance of kava extract KS 1490. Fortschr Med., 109, 119-122.
106. Wheatley, D. (1997). LI 160, an extract of St. John's Wort, versus amitriptyline in mildly to moderately depressed outpatients: A controlled 6-week clinical trial. Pharmacopsychiatry, 50(Suppl 2), 77-80.
107. Wheatley, D. (2001). Kava-kava in the treatment of generalized anxiety disorder. Primary Care Psychiatry, 7, 97-100.
108. Wheatley, D. (2002). Effect of hypericum perforatum (St. John's Wort) in major depressive disorder: A randomized controlled trial: Comment. Journal of the American Medical Association, 288, 446.
109. Whiskey, E., Werneke, U., & Taylor, D. (2001). A systematic review and meta-analysis of hypericum perforatum in depression: A comprehensive review. International Clinical Psychopharmacology, 16, 239-252.
110. Wong, A. H., Smith, M., & Boon, H. S. (1998). Herbal remedies in psychiatric practice. Archives of General Psychiatry, 55, 1033-1044.
111. Wooltorton, E., & Sibbald, B. (2002). Ephedra/ephedrine: Cardiovascular and CNS effects. Canadian Medical Association Journal, 166, 633.
112. Yager, J., Siegfreid, S. L., & DiMatteo, T. L. (1999). Use of alternative remedies by psychiatric patients: Illustrative vignettes and a discussion of the issues. American Journal of Psychiatry, 156, 1432-1438.